Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATVI Activision Blizzard	$94.42	$93.80	$70.94 ▼ $94.57	$74.29B	0.44	8.31 million shs	1 shs
GPN Global Payments	$84.29 -1.2%	$84.23	$65.93 ▼ $120.00	$20.71B	0.97	1.95 million shs	1.87 million shs
HR Healthcare Realty Trust	$18.07 -1.5%	$16.79	$14.09 ▼ $18.90	$6.45B	0.94	3.72 million shs	4.02 million shs
JELD JELD-WEN	$6.39 +1.5%	$5.43	$3.27 ▼ $16.43	$537.19M	1.68	1.82 million shs	790,326 shs
SUPN Supernus Pharmaceuticals	$43.99 -3.2%	$39.67	$29.16 ▼ $46.78	$2.55B	0.79	595,633 shs	794,454 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATVI Activision Blizzard	0.00%	0.00%	0.00%	0.00%	0.00%
GPN Global Payments	-1.25%	-3.60%	-2.93%	+10.93%	-23.68%
HR Healthcare Realty Trust	-1.58%	-0.77%	+9.75%	+21.13%	-3.81%
JELD JELD-WEN	+1.59%	-1.42%	+10.66%	+79.91%	-56.09%
SUPN Supernus Pharmaceuticals	-3.23%	-3.99%	+3.05%	+36.07%	+41.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATVI Activision Blizzard	$94.42	$93.80	$70.94 ▼ $94.57	$74.29B	0.44	8.31 million shs	1 shs
GPN Global Payments	$84.29 -1.2%	$84.23	$65.93 ▼ $120.00	$20.71B	0.97	1.95 million shs	1.87 million shs
HR Healthcare Realty Trust	$18.07 -1.5%	$16.79	$14.09 ▼ $18.90	$6.45B	0.94	3.72 million shs	4.02 million shs
JELD JELD-WEN	$6.39 +1.5%	$5.43	$3.27 ▼ $16.43	$537.19M	1.68	1.82 million shs	790,326 shs
SUPN Supernus Pharmaceuticals	$43.99 -3.2%	$39.67	$29.16 ▼ $46.78	$2.55B	0.79	595,633 shs	794,454 shs

These 7 Stocks Will Be Magnificent in 2025

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATVI Activision Blizzard	0.00%	0.00%	0.00%	0.00%	0.00%
GPN Global Payments	-1.25%	-3.60%	-2.93%	+10.93%	-23.68%
HR Healthcare Realty Trust	-1.58%	-0.77%	+9.75%	+21.13%	-3.81%
JELD JELD-WEN	+1.59%	-1.42%	+10.66%	+79.91%	-56.09%
SUPN Supernus Pharmaceuticals	-3.23%	-3.99%	+3.05%	+36.07%	+41.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATVI Activision Blizzard	0.00	N/A	N/A	N/A
GPN Global Payments	2.34	Hold	$112.21	33.13% Upside
HR Healthcare Realty Trust	2.00	Hold	$17.67	-2.21% Downside
JELD JELD-WEN	1.88	Reduce	$6.03	-5.54% Downside
SUPN Supernus Pharmaceuticals	2.50	Moderate Buy	$43.00	-2.25% Downside

Current Analyst Ratings Breakdown

Latest GPN, SUPN, JELD, HR, and ATVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/15/2025	HR Healthcare Realty Trust	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Underperform
9/10/2025	HR Healthcare Realty Trust	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/5/2025	HR Healthcare Realty Trust	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$18.00 ➝ $20.00
8/29/2025	SUPN Supernus Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$36.00 ➝ $40.00
8/28/2025	HR Healthcare Realty Trust	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$17.00 ➝ $18.00
8/27/2025	HR Healthcare Realty Trust	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Underweight	$15.00 ➝ $16.00
8/21/2025	GPN Global Payments	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/20/2025	JELD JELD-WEN	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$3.75 ➝ $5.25
8/19/2025	SUPN Supernus Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/8/2025	GPN Global Payments	Evercore ISI Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	In-Line	$85.00 ➝ $90.00
8/7/2025	GPN Global Payments	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$90.00 ➝ $100.00

(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATVI Activision Blizzard	$8.71B	8.53	$3.38 per share	27.91	$24.59 per share	3.84
GPN Global Payments	$10.07B	2.03	$19.11 per share	4.41	$91.90 per share	0.92
HR Healthcare Realty Trust	$1.27B	5.01	$0.82 per share	22.00	$15.12 per share	1.19
JELD JELD-WEN	$3.43B	0.16	$3.33 per share	1.92	$7.33 per share	0.87
SUPN Supernus Pharmaceuticals	$661.82M	3.73	$4.04 per share	10.90	$18.76 per share	2.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATVI Activision Blizzard	$1.51B	$2.73	34.59	24.09	2.61	24.87%	14.87%	10.78%	N/A
GPN Global Payments	$1.57B	$5.72	14.74	6.25	0.81	15.07%	12.47%	5.97%	10/29/2025 (Estimated)
HR Healthcare Realty Trust	-$654.48M	-$1.15	N/A	11.08	N/A	-32.95%	-7.70%	-3.78%	10/29/2025 (Estimated)
JELD JELD-WEN	-$189.02M	-$4.06	N/A	∞	N/A	-10.03%	-1.60%	-0.35%	11/3/2025 (Estimated)
SUPN Supernus Pharmaceuticals	$73.86M	$1.15	38.25	30.55	N/A	9.70%	14.22%	10.82%	11/3/2025 (Estimated)

Latest GPN, SUPN, JELD, HR, and ATVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	GPN Global Payments	$3.06	$3.10	+$0.04	$0.99	$2.36 billion	$2.36 billion
7/31/2025	Q2 2025	HR Healthcare Realty Trust	$0.40	$0.41	+$0.01	$0.41	$290.83 million	$287.07 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATVI Activision Blizzard	$0.99	1.05%	N/A	36.26%	1 Years
GPN Global Payments	$1.00	1.19%	N/A	17.48%	N/A
HR Healthcare Realty Trust	$0.96	5.31%	N/A	N/A	N/A
JELD JELD-WEN	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest GPN, SUPN, JELD, HR, and ATVI Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2025	GPN Global Payments	quarterly	$0.25	1.17%	9/12/2025	9/12/2025	9/26/2025
7/31/2025	HR Healthcare Realty Trust	quarterly	$0.24	6.25%	8/14/2025	8/14/2025	8/28/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATVI Activision Blizzard	0.17	4.66	4.66
GPN Global Payments	0.61	0.95	0.95
HR Healthcare Realty Trust	0.01	N/A	N/A
JELD JELD-WEN	2.42	1.77	1.04
SUPN Supernus Pharmaceuticals	N/A	2.58	2.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATVI Activision Blizzard	81.93%
GPN Global Payments	89.76%
HR Healthcare Realty Trust	N/A
JELD JELD-WEN	95.04%
SUPN Supernus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ATVI Activision Blizzard	1.08%
GPN Global Payments	1.01%
HR Healthcare Realty Trust	0.37%
JELD JELD-WEN	1.24%
SUPN Supernus Pharmaceuticals	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATVI Activision Blizzard	13,000	786.80 million	778.30 million	Optionable
GPN Global Payments	27,000	242.61 million	240.16 million	Optionable
HR Healthcare Realty Trust	580	351.61 million	350.31 million	Optionable
JELD JELD-WEN	16,000	85.40 million	84.34 million	Optionable
SUPN Supernus Pharmaceuticals	580	56.07 million	51.14 million	Optionable

GPN, SUPN, JELD, HR, and ATVI Headlines

Recent News About These Companies

Rhumbline Advisers Sells 7,121 Shares of Supernus Pharmaceuticals, Inc. $SUPN

September 15 at 3:45 AM | marketbeat.com

Villanova Investment Management Co LLC Has $641,000 Stock Position in Supernus Pharmaceuticals, Inc. $SUPN

September 13 at 6:33 AM | marketbeat.com

Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Great Lakes Advisors LLC

September 12, 2025 | marketbeat.com

Supernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells $292,645.38 in Stock

September 11, 2025 | marketbeat.com

Axiom Investors LLC DE Sells 15,521 Shares of Supernus Pharmaceuticals, Inc. $SUPN

September 11, 2025 | marketbeat.com

Supernus Pharmaceuticals (NASDAQ:SUPN) CEO Jack Khattar Sells 55,578 Shares

September 10, 2025 | marketbeat.com

Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 52-Week High - Here's Why

September 10, 2025 | marketbeat.com

CEO’s Major Stock Sale Shakes Up Supernus Pharmaceuticals

September 9, 2025 | tipranks.com

Can Mixed Fundamentals Have A Negative Impact on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Current Share Price Momentum?

September 9, 2025 | finance.yahoo.com

Supernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells $2,557,143.78 in Stock

September 9, 2025 | insidertrades.com

Unpacking Q2 Earnings: Eli Lilly (NYSE:LLY) In The Context Of Other Branded Pharmaceuticals Stocks

September 8, 2025 | finance.yahoo.com

Supernus Pharmaceuticals, Inc. $SUPN Stock Position Cut by PDT Partners LLC

September 6, 2025 | marketbeat.com

Supernus Pharmaceuticals, Inc. $SUPN Stock Position Raised by Cubist Systematic Strategies LLC

September 6, 2025 | marketbeat.com

Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 52-Week High - What's Next?

September 4, 2025 | marketbeat.com

Trexquant Investment LP Has $4.73 Million Holdings in Supernus Pharmaceuticals, Inc. $SUPN

September 3, 2025 | marketbeat.com

Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by Armistice Capital LLC

September 2, 2025 | marketbeat.com

Northern Trust Corp Cuts Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN

September 2, 2025 | marketbeat.com

2 Healthcare Stocks on Our Watchlist and 1 We Avoid

September 1, 2025 | uk.finance.yahoo.com

Ashford Capital Management Inc. Purchases 20,781 Shares of Supernus Pharmaceuticals, Inc. $SUPN

September 1, 2025 | marketbeat.com

Piper Sandler Raises Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target to $40.00

August 31, 2025 | marketbeat.com

Hsbc Holdings PLC Sells 180,627 Shares of Supernus Pharmaceuticals, Inc. $SUPN

August 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GPN, SUPN, JELD, HR, and ATVI Company Descriptions

Activision Blizzard NASDAQ:ATVI

Activision Blizzard, Inc., together with its subsidiaries, develops and publishes interactive entertainment content and services in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through three segments: Activision, Blizzard, and King. It develops and distributes content and services on video game consoles, personal computers, and mobile devices, including subscription, full-game, and in-game sales, as well as by licensing software to third-party or related-party companies that distribute Activision and Blizzard products. The company also maintains a proprietary online gaming service, Battle.net that facilitates digital distribution of content, online social connectivity, and the creation of user-generated content. In addition, it operates esports leagues and offer digital advertising content; and provides warehousing, logistics, and sales distribution services to third-party publishers of interactive entertainment software, as well as manufacturers of interactive entertainment hardware products. The company's key product franchises include Call of Duty, World of Warcraft, Diablo, Hearthstone, Overwatch, Overwatch League, and Candy Crush. It serves retailers and distributors, including mass-market retailers, consumer electronics stores, discount warehouses, and game specialty stores through third-party distribution and licensing arrangements. The company was founded in 1979 and is headquartered in Santa Monica, California.

Global Payments NYSE:GPN

$84.28 -1.07 (-1.25%)

Closing price 09/15/2025 03:59 PM Eastern

Extended Trading

$84.30 +0.01 (+0.01%)

As of 09/15/2025 07:46 PM Eastern

Global Payments Inc. provides payment technology and software solutions for card, check, and digital-based payments in the Americas, Europe, and the Asia-Pacific. It operates through two segments, Merchant Solutions and Issuer Solutions. The Merchant Solutions segment offers authorization, settlement and funding, customer support, chargeback resolution, terminal rental, sales and deployment, payment security, and consolidated billing and reporting services. This segment also provides an array of enterprise software solutions that streamline business operations of its customers in various vertical markets; and value-added solutions and services, such as point-of-sale software, analytics and customer engagement, payroll and reporting, and human capital management. The Issuer Solutions segment offers solutions that enable financial institutions and retailers to manage their card portfolios through a platform; and commercial payments, account payables, and electronic payment alternatives solutions for businesses and governments. It markets its products and services through direct sales force, trade associations, agent and enterprise software providers, referral arrangements with value-added resellers, and independent sales organizations. The company was founded in 1967 and is headquartered in Atlanta, Georgia.

Healthcare Realty Trust NYSE:HR

$18.07 -0.28 (-1.50%)

Closing price 09/15/2025 03:59 PM Eastern

Extended Trading

$17.71 -0.35 (-1.96%)

As of 09/15/2025 07:28 PM Eastern

Healthcare Realty Trust, Inc. provides real estate investment services. It owns, leases, manages, acquires, finances, develops, and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States of America. The company was founded by David R. Emery in 1992 and is headquartered in Nashville, TN.

JELD-WEN NYSE:JELD

$6.38 +0.10 (+1.51%)

Closing price 09/15/2025 03:59 PM Eastern

Extended Trading

$6.38 0.00 (0.00%)

As of 09/15/2025 04:11 PM Eastern

JELD-WEN Holding, Inc. designs, manufactures, and sells wood, metal, and composite materials doors, windows, and related building products in North America and Europe. The company offers a line of residential interior and exterior door products, including patio doors, and folding or sliding wall systems; non-residential doors; stile and rail doors; and wood, vinyl, and wood composite windows. It also provides other ancillary products and services, such as trim boards, glasses, hardware and locks, window screens, and molded door skins, as well as miscellaneous installation and other services. The company sells its products under the JELD-WEN, AuraLast, MiraTEC, Extira, LaCANTINA, MMI Door, Karona, ImpactGard, JW, Aurora, IWP, True BLU, ABS, Siteline, National Door, Low-Friction Glider, Hydrolock, VPI, AURALINE, FINISHIELD, MILLENNIUM, TRUFIT, EPICVUE, EVELIN, Swedoor, Dooria, DANA, Mattiovi, Zargag, Alupan, Domoferm, Kellpax, and HSE brands. It serves wholesale distributors and retailers, retail home centers, and building product dealers, as well as homebuilders, contractors, and consumers. JELD-WEN Holding, Inc. was founded in 1960 and is based in Charlotte, North Carolina.

Supernus Pharmaceuticals NASDAQ:SUPN

$43.99 -1.47 (-3.23%)

Closing price 09/15/2025 04:00 PM Eastern

Extended Trading

$44.00 +0.00 (+0.01%)

As of 09/15/2025 04:20 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GPN, SUPN, JELD, HR, and ATVI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GPN, SUPN, JELD, HR, and ATVI Earnings

Compare Dividends

Latest GPN, SUPN, JELD, HR, and ATVI Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GPN, SUPN, JELD, HR, and ATVI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GPN, SUPN, JELD, HR, and ATVI Company Descriptions

Activision Blizzard NASDAQ:ATVI

Global Payments NYSE:GPN

Healthcare Realty Trust NYSE:HR

JELD-WEN NYSE:JELD

Supernus Pharmaceuticals NASDAQ:SUPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools